Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Advanced method for evaluation of gastric cancer risk by serum markers

This month's issue of Helicobacter reports on an advanced method for evaluation of gastric cancer risk by serum markers to determine true low-risk subjects for gastric neoplasm.

News image

Patients with negative anti-Helicobacter pylori antibody titer and high pepsinogen (PG) level (Group A) are regarded as having a low risk for gastric cancer.

However, gastric cancer cases are occasionally observed in this group.

Dr Masanori Ito and colleagues from Japan elucidated the clinical features of gastric neoplasm in Group A patients and reviewed advanced methods for mass screening.

A total of 271 gastric epithelial neoplasm patients were enrolled.

The research team classified them according to the Helicobacter pylori-pepsinogen system and determined the number of patients in each group.

After excluding trueHelicobacter pylori-negative cases from Group A, the team examined the differences between Group A and Group non-A.

Group A included 30 patients, and only 3 of these were true negative for Helicobacter pylori.

Histologically, 89% had little inflammation

Helicobacter

The team observed that all patients in Group A exhibited endoscopic atrophy in the gastric corpus.

Serologically, these patients showed low gastrin, low pepsinogen II and high pepsinogen I/II ratio, indicative of post-eradication.

Histologically, 89% of these had little inflammation, and 96% were negative for Helicobacter pylori by immunohistochemistry.

The team observed no difference in the incidence of metachronous gastric tumors between Group A and Group non-A.

The discriminant function using gastrin and pepsinogens could distinguish these 27 patients from true Helicobacter pylori-negative controls with 85% sensitivity and 84% specificity.

Dr Ito's team concludes, "Group A included a certain number of patients with atrophic gastritis who were potentially at risk of gastric neoplasm development."

"Although evaluation of corpus atrophy is necessary for the identification of these patients, the discriminant function may be useful."

Helicobacter 2014: 19(1): 18
19 February 2014

Go to top of page Email this page Email this page to a colleague

 28 May 2015

Advanced search
 28 May 2015 
Bleeding and colorectal endoscopic submucosal dissection
 28 May 2015 
Excercise and IBD
 28 May 2015 
Probiotics and Crohn's disease
 27 May 2015 
Management of constipation and IBS
 27 May 2015 
Vegetables and fruit and IBD
 27 May 2015 
Radiofrequency ablation for treatment of GERD
 26 May 2015 
Calcium channel blockers and GI bleeds
 26 May 2015 

Risk factors for celiac disease

 26 May 2015 
Antimicrobials for intraabdominal infection
 25 May 2015 
Risk of GI bleeds with NSAIDs
 25 May 2015 
Colorectal cancer screening
 25 May 2015 
Saccharomyces boulardii and H. pylori
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 22 May 2015 
Colonoscopy screening for colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 20 May 2015 
Refractory metastatic colorectal cancer
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Pancreatic neuroendocrine tumors
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 19 May 2015 
Metabolic syndrome and Barrett's
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 18 May 2015 
ESPGHAN celiac guidelines
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Hypnotherapy in IBS/IBD
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us